Invesco Ltd. Monte Rosa Therapeutics, Inc. Transaction History
Invesco Ltd.
- $503 Billion
- Q1 2025
A detailed history of Invesco Ltd. transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 35,346 shares of GLUE stock, worth $162,591. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,346
Previous 12,847
175.13%
Holding current value
$162,591
Previous $89,000
84.27%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding GLUE
# of Institutions
107Shares Held
53.4MCall Options Held
69.1KPut Options Held
22.4K-
Nea Management Company, LLC Timonium, MD7.69MShares$35.4 Million3.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.64MShares$30.6 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.66MShares$26 Million1.15% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$26 Million54.61% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$22.6 Million0.27% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $215M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...